New drug duo tested in fight against spreading prostate cancer
NCT ID NCT07244341
Summary
This is an early-stage trial testing the safety and initial effectiveness of combining two drugs, valemetostat and darolutamide, for men with metastatic castration-resistant prostate cancer (mCRPC). The study will enroll about 60 men whose cancer has spread and is no longer responding to standard hormone-blocking treatments. The main goal is to find a safe dose and see if the combination can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGKōtoku, 135-8550, Japan
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29572-4607, United States
-
Kobe City Med Cen Gen Hosp.
RECRUITINGKobe, 650-0047, Japan
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229-6028, United States
-
Toho University Sakura Medical Center
RECRUITINGSakura-shi, 285-8741, Japan
-
Virginia Cancer Specialists (NEXT Virginia)
RECRUITINGFairfax, Virginia, 22031-2171, United States
Conditions
Explore the condition pages connected to this study.